Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lung cancer (NSCLC), in being tested for EGFR mutations, leaving some without access to the most appropriate treatment for them.
U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
India's first injectible inactivated polio vaccine (IPV) was on Monday launched by Health Minister J.P. Nadda as part of the country's commitment to global polio eradication.
The European Commission has approved Boehringer Ingelheim's Praxbind (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding. Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be approved in the European Union.
Mylan N.V. announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
GSK announced that dosing has commenced in a phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with giant cell arteritis (GCA).
Takeda Pharmaceutical Company Limited announced that the multiple sclerosis treatment drug, "Copaxone® Subcutaneous Injection 20 mg Syringe" (generic name: glatiramer acetate, hereinafter "Copaxone") has become available in Japan.
This drug has been developed by Teva Pharmaceutical Industries Ltd. (Head office Petah Tikva, Israel hereinafter "Teva") as a subcutaneous injection administered once daily, to prevent the relapse of multiple sclerosis. Copaxone was designated as an orphan drug by the Japanese Ministry of Health, Labour and Welfare (MHLW) in March 2009, and a request was received from the MHLW in May 2010 for its development as an "unapproved drug highly needed in medical care". In March 2013, Takeda and Teva entered into a licensing agreement for commercialization of this drug in Japan, and on September 28, 2015 Takeda obtained NDA approval.
Multiple sclerosis is assumed to be an autoimmune disease, the hallmark sign of which is inflammatory demyelination of the central nervous system characterized by demyelinating plaques in the brain and the spinal cord. Common symptoms of multiple sclerosis include visual problems, ocular motor abnormality, paresthesia, muscle weakness, spasticity, urinary dysfunction, and cognitive impairment. This disease may present as a primary progressive type, which takes a chronic progressive course from its early onset; a relapsing-remitting type, which repeats a pattern of relapse and remission; or a secondary progressive type that shifts to a progressive course later. More than 80% of patients are categorized as having the relapsing-remitting type. Multiple sclerosis is estimated to affect approximately 18,000 individuals in Japan, with its prevalence tending to increase.
"Copaxone, one of the most frequently used drugs in multiple sclerosis, is approved in more than 50 countries worldwide, and is expected to represent a new treatment option for Japanese patients," said Masato Iwasaki, Ph.D., Director and President, Japan Pharma Business Unit of Takeda. "Takeda will continue to be committed to delivering drugs for diseases that remain as high unmet medical needs for both patients and physicians".
Men with Type 2 diabetes who have low testosterone levels can benefit significantly from testosterone treatment, says a new study led by an Indian-American doctor.
Medicines do not appear to degrade faster in the zero-gravity atmosphere on the International Space Station (ISS) and this does not differ from what is typically seen on the Earth, researchers report.
Children who are left without direct parental care for extended periods of time show larger gray matter volumes in the brain and may also show delay in brain development, according to a new study.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
